<DOC>
	<DOCNO>NCT01646593</DOCNO>
	<brief_summary>The objective trial provide regorafenib subject diagnose metastatic / unresectable GIST progress standard therapy . Selected additional safety information regorafenib collect progression-free survival ( PFS ) estimate .</brief_summary>
	<brief_title>Regorafenib Subjects With Gastrointestinal Stromal Tumors ( GIST ) Who Have Progressed After Standard Therapy</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<criteria>Male female subject &gt; = 18 year age Subjects histologically confirm metastatic / unresectable GIST At least imatinib sunitinib prior treatment regimen progression intolerance imatinib sunitinib Adequate bone marrow , liver renal function Women childbearing potential men must agree use adequate contraception enter program least 8 week last study drug administration . The investigator designate associate request advise subject achieve adequate birth control . Adequate contraception define study medically recommend method ( combination method ) per standard care . Prior treatment regorafenib Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior start study drug Pregnant breastfeeding subject . Women childbearing potential must pregnancy test perform maximum 7 day start treatment , negative result must document start study drug . Congestive heart failure &gt; = New York Heart Association ( NYHA ) class 2 Unstable angina ( angina symptom rest ) , newonset angina ( begin within last 3 month ) Myocardial infarction le 6 month start study drug Cardiac arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) Uncontrolled hypertension ( Systolic blood pressure &gt; 140 mmHg diastolic pressure &gt; 90 mmHg despite optimal medical management ) Pleural effusion ascites cause respiratory compromise ( National Cancer Institute Common terminology criterion adverse event [ NCICTCAE ] v. 4.0 Grade &gt; = 2 dyspnea ) Ongoing infection NCICTCAE v. 4.0 Grade &gt; 2 Known history human immunodeficiency virus ( HIV ) infection Active hepatitis B C , chronic hepatitis B C require treatment antiviral therapy Subjects seizure disorder require medication History organ allograft Subjects evidence history bleed diathesis , irrespective severity Any hemorrhage bleeding event NCICTCAE v. 4.0 Grade &gt; = 3 within 4 week prior start study medication Nonhealing wound , ulcer , bone fracture Renal failure require hemo peritoneal dialysis Dehydration NCICTCAE v. 4.0 Grade &gt; = 1 Substance abuse , medical , psychological social condition may interfere subject 's participation study evaluation study result Known hypersensitivity study drug , study drug class , excipients formulation Any illness medical condition unstable could jeopardize safety subject / compliance study Interstitial lung disease ongoing sign symptom Persistent proteinuria NCICTCAE v. 4.0 Grade 3 ( &gt; 3.5 g/24 hour ) Subjects unable swallow oral medication Any malabsorption condition Unresolved toxicity high NCICTCAE v. 4.0 Grade 1 ( exclude alopecia , anaemia , hypothyroidism ) attribute prior therapy / procedure Concomitant participation participation another therapeutic trial investigational new drug within 30 day 5 drug halflives ( drug half life subject know ) , whichever short If approve tyrosine kinase inhibitor give within 1 week minimum 5 drug halflives whichever longer ( i.e . within 7 day imatinib , within 10 day sunitinib )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>